Message #28 From:
NewsBot Date: November 18, 2006 12:20:00 PM
CHHH News China Health Holding Attends National Investment Banking Association Conference in Las Vegas
LAS VEGAS--(BUSINESS WIRE)--China Health Holding (OTCBB:CHHH), a developer, manufacturer,
marketer and distributor in the global medical and pharmaceutical
industry in China and worldwide, announced today the Company’s
Founder/CEO Julianna Lu will attend the National Investment Banking
Association Conference in Las Vegas, NV on Nov. 30 - Dec. 1, 2006, to
raise the Company’s profile and visibility on
Wall Street. National Investment Banking Association (NIBA) is a
national trade association of regional and independent brokerages,
investment banking firms, and related capital market service providers.
NIBA member firms have successfully completed some 850+ equity offerings
totaling approximately $9 billion in new capital for America's finest
emerging growth companies.
Currently,Los Angeles-based Investor Relations International (“IRI”,
www.irintl.com),
as investor relations counsel/partner for the Company, is executing a
three (3) years long term IR Program to raise investor awareness of the
company's performance through a multi-channel campaign. IRI will employ
print and electronic media as well as direct communication with money
managers and current or prospective shareholders. The IRI program,
focused on communicating China Health's expansion strategy across China,
seeks both to broaden the Company's shareholder base and to solidify the
long-term loyalty of current shareholders. The one crucial element we
have lacked up to this point is a strong investor-relations program to
raise our profile on Wall Street and give us better access to the
capital markets should we require it. Our IR partnership with IRI fills
that gap, and we expect to benefit from much greater visibility and
liquidity from here on. If you would like to be added to China Health's
investor email lists or have additional questions, please contact Haris
Tajyar with Investor Relations International at htajyar@irintl.com,
or/and info@chinahealthholding.com.
About China Health Holding
China Health Holding, Inc. is a developer, manufacturer and marketer for
natural medicinal products and pharmaceutical drug pipeline in China and
worldwide, with an extensive knowledge and expertise in the field of
Traditional Chinese Medicine and China Pharmaceutical Industry. The
Company's immediate goal is profitable penetration of the growing global
and China pharmaceutical industry and market. Also to seek and develop
and complete potential acquisition candidates with major pharmaceutical
companies in PR China and worldwide to secure a strong future and
powerful position in the global and PR China pharmaceutical industry.
Long-term plans include the development of a pharmaceutical drug
pipeline and technology based on the Company's access to the knowledge
of Traditional Chinese Medicine and PR China pharmaceutical industry.
The Company is supported by two cores, wholly owned subsidiaries: 1.
China Health World Pharmaceutical Corporation, which will develop,
manufacture and commercialize natural medications for epidemic diseases
and conditions related to mellitus, cardiovascular and cerebral-vascular
system dysfunctions, and neurological disorders. 2. China Health World
Trade Corporation, which will support the Company in the areas of
worldwide to develop China Health’s
retain/franchise stores/infrastructure and worldwide branding,
multimedia marketing and multi-channel distribution to global customers
and markets.
Recent Development and Acquisition
Progress:
The Company controls/owns exclusive worldwide ownership/rights for a
total of 134 proprietary natural herbal medicinal products/formulas as
Two Natural Herbal Medicinal Product lines: King of Herbs products and
Taoist Medicinal products. The Company is developing and execution for
further worldwide branding, multimedia marketing and multi-channel
distribution, and worldwide retail and franchise stores/infrastructure
to global customers and markets.
CHHH has executed a definitive acquisition agreement to acquire 60% of
Henan Furen Huaiqingtang Pharmaceuticals Co. Ltd, and CHHH has executed
a definitive acquisition agreement to acquire 100% of Shaanxi MeiChen
Pharmaceuticals Co. Ltd.
CHHH recently has also entered into acquisitions letters of intent to
acquire 51% or more of the following pharmaceutical companies in PR
China with legal first refusal and exclusive rights with: Beijing Boran
Pharmaceutical Co. Ltd.; and Shaanxi Wanan Pharmaceuticals Co. Ltd.; and
Henan Tiankang Pharmaceuticals Co. Ltd.
CHHH believes that the completion of these acquisitions will enable it
to vertically integrate its operations from manufacturing, developing
and marketing Chinese herbal-based medicinal products, as well as a
pharmaceutical drug pipeline, to full distribution and marketing across
PR China, therefore substantially increasing profit margins.
Acquisitions should accelerate growth of revenues and earnings. A
strategic combination of assets, net income, an enhanced pharmaceutical
drug pipeline and technologies will accrete value to the Company and its
shareholders.
In addition, CHHH also recently signed a letter of intent with WangJing
Hospital and the WangJing Hospital of China Academy of Chinese Medical
Sciences, PR China, in order to develop the China International
University of Traditional Chinese Medicine and the University Hospital
for Traditional Chinese Medical Sciences.
About Investor Relations International
Investor Relations International (IRI), based in Los Angeles, is a
leading investor relations firm serving a worldwide client base. The
principals of IRI have developed award-winning investor relations
programs for a number of NYSE and Nasdaq-listed companies such as Insmed
Inc., Internet Capital Group, LJ International, Starwood Hotels &
Resorts Worldwide, ValueVision International and others, and have
assisted dozens of public companies ranging from emerging small-cap
companies to multinational corporations with market capitalizations in
excess of $15 billion. IRI designs and implements customized investor
relations programs to meet each client's unique needs. It enjoys one of
the highest client retention rates in the industry.
Safe Habour
To the extent that statements in the press release are not strictly
historical, including statements as to revenue projections, business
strategy, outlook, objectives, future milestones, plans, intentions,
goals, future financial conditions, future collaboration agreements, the
success of the Company's development, events conditioned on stockholder
or other approval, or otherwise as to future events, such statements are
forward looking, all forward-looking statements, whether written or
oral, and whether made by or on behalf of the Company, are expressly
qualified by the cautionary statements and any other cautionary
statements, which may accompany the forward-looking statements, and are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained
in this release are subject to certain risks and uncertainties that
could cause actual results to differ materially from the statements
made. Other important factors that could cause actual results to differ
materially include the following: business conditions and the amount of
growth in the Company's industry and general economy; competitive
factors; ability to attract and retain personnel; the price of the
Company's stock; and the risk factors set forth from time to time in the
Company's SEC reports, including but not limited to its annual report on
Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on
Form 8-K. In addition, the company disclaims any obligation to update or
correct any forward-looking statements in all of the Company's press
releases to reflect events or circumstances after the date hereof.
